2024
Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb A, Strober B, Merola J, Mostaghimi A, Farberg A, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s490. DOI: 10.25251/skin.8.supp.490.Peer-Reviewed Original ResearchGeneralized pustular psoriasisPhysician global assessmentSkin symptomsPustular psoriasisGlobal assessmentProportion of patientsPercentage of patientsTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsClear skinSpesolimabPatientsContinuous treatmentMonoclonal antibodiesSkin diseasesPatient burdenSymptomsPsoriasisTotal scoreSkinTreatment
2023
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Strober B, Ferris L, Callis Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 90: 82-90. PMID: 37739267, DOI: 10.1016/j.jaad.2023.08.097.Peer-Reviewed Original ResearchDermatology Life Quality Index scoresLife Quality Index scoresPsoriasis RegistryQuality Index scoresSevere psoriasisPsoriasis symptomsClear skinIndex scoreReal-world treatment effectivenessPrior biologic treatmentSevere plaque psoriasisInflammatory skin diseasePatient-reported outcomesEntire study populationReal-world effectivenessSignificant reductionPlaque psoriasisEligible adultsPatient adherenceBiologic treatmentActivity impairmentObservational studyStudy populationRisankizumabPsoriasis
2016
Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski B, Gottlieb A, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. Journal Of Psoriasis And Psoriatic Arthritis 2016, 1: 167-174. DOI: 10.1177/247553031600100406.Peer-Reviewed Original ResearchPsoriasis-related itchingSevere plaque psoriasisPhase 3 studyComplete symptom reliefWeeks of treatmentProportion of respondersGreater symptom improvementSymptom respondersPlaque psoriasisPsoriasis symptomsSymptom reliefComplete reliefSustained efficacySymptom improvementPsoriasis treatmentResults SubjectsSecukinumabEtanerceptItchingPainClear skinPlaceboMonoclonal antibodiesTreatment effectsPatients